University of Texas Health Science Center at Houston

1. Novartis Pharmaceuticals Corporation $5,097,354 43 payments
2. Akebia Therapeutics Inc $2,275,778 24 payments
3. AbbVie, Inc. $2,026,996 211 payments
4. Gilead Sciences, Inc. $882,406 183 payments
5. Intercept Pharmaceuticals, Inc. $450,844 163 payments
6. Medtronic, Inc. $447,866 94 payments
7. Marinus Pharmaceuticals, Inc. $385,258 36 payments
8. Pfizer Inc. $362,330 139 payments
9. Incyte Corporation $323,399 29 payments
10. PTC Therapeutics, Inc. $303,435 57 payments

1. A Prospective Phase II, Open-Label, Single-Arm, Multicenter, Study to Assess Efficacy and Safety of Seg101 (Crizanlizumab), in Sickle Cell Disease Patients With Priapism $1,441,568 6 payments
2. Vadadustat for the Prevention and Treatment of Acute Respiratory Distress Syndrome (ARDS) in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19) $1,323,109 19 payments
3. A Phase III, Multicenter, Randomized, Placebo Controlled, Double-Blind Study to Assess Efficacy and Safety of Two Doses of Crizanlizumab Versus Placebo, With Or Without Hydroxyurea /Hydroxycarbamide Therapy, in Adolescent and Adult Sickle Cell Disease Patients With Vaso-Occlusive Crises $1,004,050 3 payments
4. A Phase III, Multicenter, Randomized, Placebo Controlled, Double-Blind Study to Assess Efficacy and Safety of Two Doses of Crizanlizumab Versus Placebo, With Or Without Hydroxyurea /Hydroxycarbamide Therapy, in Adolescent and Adult Sickle Cell Disease Pat $831,071 3 payments
5. M15-566 $689,847 26 payments
6. Vadadustat for the prevention and treatment ARDS due to suspected aspiration, pathogen-associated pneumonia, or sepsis $600,000 2 payments
7. A Randomized Double Blind Placebo Controlled Parallel Group Study to Evaluate the Efficacy of Two Doses of Cnp520 in Participants at Risk for the Onset of Clinical Symptoms of Ad $591,986 1 payment
8. Slate $399,594 46 payments
9. Vadadustat for the Prevention and Treatment of Acute Respiratory Distress Syndrome (Ards) in Hospitlized Patients With Coronavirus Disease 2019 (Covid-19) $352,670 3 payments
10. A Phase 3, Open-label Study of Adjunctive Ganaxolone (GNX) Treatment in Children and Adults With Tuberous Sclerosis Complex (TSC)-Related Epilepsy (TrustTSC OLE) $337,639 24 payments

1. Other $278,147 3 payments
2. Patient care $265,687 4 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.